<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222663</url>
  </required_header>
  <id_info>
    <org_study_id>2010-67-PMX</org_study_id>
    <nct_id>NCT01222663</nct_id>
  </id_info>
  <brief_title>Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock</brief_title>
  <acronym>ABDO-MIX</acronym>
  <official_title>Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meditor SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meditor SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, comparative, open and multi-centre study is to show that two
      sessions of hemoperfusion with Toraymyxin performed within maximum 36 hours after the surgery
      of a peritonitis by hollow organ perforation reduce the mortality in patients suffering from
      septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality rate due to peritonitis associated to a severe sepsis or a septic shock remains
      high (between 40 and 60% as per the studies). The recent complementary therapies for severe
      sepsis have been reassessed (strict glycaemic control, substitutive corticotherapy, activated
      protein C). Early neutralisation of the endotoxaemia related to gram-negative bacilli sepsis
      in contact with hemoperfusion membrane covered with polymyxin B (Toraymyxin™) may enable
      reduction of the inflammatory reaction caused by sepsis and improve its prognosis. 30
      studies, including 10 randomized studies, have compared hemoperfusion with Toraymyxin™ to the
      standard treatment, showing an improvement in the patients' haemodynamic state, oxygenation
      conditions and reduction in mortality. This treatment is commonly used in Japan. However, the
      studies conducted either include only a limited number of patients or are not randomized
      prospective studies. The post-hoc analysis of a recent randomized study conducted on a
      limited number of patients with abdominal septic shock shows a significant reduction in
      mortality after factor adjustment. Though the side effects of such a treatment are limited,
      its cost is high. Hence, extensive prospective studies are necessary to confirm its
      effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>organ failure assessed by SOFA score</measure>
    <time_frame>day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delay to withdraw catecholamine after initial shock</measure>
    <time_frame>day 1-day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality between the two groups at 7 dayx, 14 days, 21 days and 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events related to hemoperfusion technique including anticoagulation therapy such as bleeding (type and number of blood transfusion)</measure>
    <time_frame>day1-day4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Peritonitis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard therapy + 2 sessions of hemoperfusion within the first 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <description>Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_label>Hemoperfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion</intervention_name>
    <description>Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.</description>
    <arm_group_label>Hemoperfusion</arm_group_label>
    <other_name>toraymyxin</other_name>
    <other_name>PMX-20R</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed community or nosocomial acquired peritonitis due to organ perforation

          -  Septic shock requiring catecholamine infusion started or maintained 2 hours after
             surgery

        Exclusion Criteria:

          -  Pregnancy

          -  No severity criteria within the 8 hours following surgery

          -  Neutropenia due to chemotherapy or malignancy

          -  Abdominal sepsis without peritonitis

          -  Mesenteric ischemia without perforation

          -  Peritonitis due to appendicitis

          -  Perforation linked to trauma

          -  Cirrhosis child C

          -  Impossibility to use heparin

          -  Prolonged cardiac arrest within 72h before surgery

          -  Terminal disease diagnosed during surgery

          -  Moribund subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Payen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisière University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>René Robert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dieppe Hospital</name>
      <address>
        <city>Dieppe</city>
        <zip>76202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vendée Hospital</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Schaffner Hospital</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Source Hospital</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lariboisière University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jean Hospital</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchaillou University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roanne Hospital</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Malo Hospital</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritonitis</keyword>
  <keyword>septic shock</keyword>
  <keyword>hemoperfusion</keyword>
  <keyword>Polymyxin B</keyword>
  <keyword>endotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

